Neoadjuvant and Adjuvant Systemic Therapies in Loco-Regional Treatments for Hepatocellular Carcinoma: Are We at the Dawn of a New Era?
adjuvant therapy
hepatocellular carcinoma
immune checkpoint inhibitors
immunotherapy
neoadjuvant therapy
recurrence
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
27 May 2023
27 May 2023
Historique:
received:
14
04
2023
revised:
20
05
2023
accepted:
26
05
2023
medline:
10
6
2023
pubmed:
10
6
2023
entrez:
10
6
2023
Statut:
epublish
Résumé
Despite maximizing techniques and patient selection, liver resection and ablation for HCC are still associated with high rates of recurrence. To date, HCC is the only cancer with no proven adjuvant or neoadjuvant therapy used in association to potentially curative treatment. Perioperative combination treatments are urgently needed to reduce recurrence rates and improve overall survival. Immunotherapy has demonstrated encouraging results in the setting of adjuvant and neoadjuvant treatments for non-hepatic malignancies. Conclusive data are not yet available in the context of liver neoplasms. However, growing evidence suggests that immunotherapy, and in particular immune checkpoint inhibitors, could represent the cornerstone of an epochal change in the treatment of HCC, improving recurrence rates and overall survival through combination treatments. Furthermore, the identification of predictive biomarkers of treatment response could drive the management of HCC into the era of a precision medicine. The purpose of this review is to analyze the state of the art in the setting of adjuvant and neoadjuvant therapies for HCC in association with loco-regional treatments in patients not eligible for liver transplantation and to hypothesize future scenarios.
Identifiants
pubmed: 37296912
pii: cancers15112950
doi: 10.3390/cancers15112950
pmc: PMC10251995
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
J Gastrointest Oncol. 2021 Dec;12(6):2930-2942
pubmed: 35070419
Gastroenterology. 2015 Jun;148(7):1383-91.e6
pubmed: 25747273
J Hepatocell Carcinoma. 2022 Mar 08;9:127-140
pubmed: 35300207
Biomed Pharmacother. 2017 Apr;88:395-402
pubmed: 28122304
Liver Cancer. 2021 Jul;10(4):296-308
pubmed: 34414118
N Engl J Med. 2008 Jul 24;359(4):378-90
pubmed: 18650514
Lancet Oncol. 2019 Feb;20(2):282-296
pubmed: 30665869
Future Oncol. 2020 May;16(15):975-989
pubmed: 32352320
Hepatology. 2021 Feb;73(2):661-673
pubmed: 32324905
Lancet Oncol. 2022 Jan;23(1):77-90
pubmed: 34914889
Expert Rev Gastroenterol Hepatol. 2021 Jun;15(6):643-656
pubmed: 33445990
Cancer Immunol Immunother. 2019 Jan;68(1):23-32
pubmed: 30232520
Oncologist. 2020 Oct;25(10):e1541-e1551
pubmed: 32472951
BJS Open. 2022 Sep 2;6(5):
pubmed: 36125345
Viruses. 2021 Nov 09;13(11):
pubmed: 34835054
World J Surg Oncol. 2021 Jun 10;19(1):168
pubmed: 34112190
J Hepatol. 2022 Apr;76(4):862-873
pubmed: 34902530
Future Oncol. 2022 Oct;18(33):3769-3782
pubmed: 36399155
Lancet Oncol. 2009 Jan;10(1):25-34
pubmed: 19095497
Scand J Gastroenterol. 2015 May;50(5):567-76
pubmed: 25615260
Front Med. 2021 Apr;15(2):155-169
pubmed: 33754281
Ann Surg. 2017 Oct;266(4):693-701
pubmed: 28650354
Zhonghua Wai Ke Za Zhi. 2022 Jul 1;60(7):688-694
pubmed: 35775262
J Cancer Res Ther. 2018;14(4):807-814
pubmed: 29970657
Gastroenterology. 2022 Mar;162(3):920-934
pubmed: 35210014
Cancer Immunol Res. 2016 May;4(5):419-30
pubmed: 26968206
J Immunol. 2006 Jun 15;176(12):7686-94
pubmed: 16751416
J Immunother Cancer. 2022 Apr;10(4):
pubmed: 35379737
Cell Cycle. 2012 Aug 1;11(15):2843-55
pubmed: 22801548
J Pers Med. 2021 Oct 17;11(10):
pubmed: 34683182
Clin Cancer Res. 2004 Mar 1;10(5):1574-9
pubmed: 15014006
HPB (Oxford). 2019 Dec;21(12):1687-1696
pubmed: 31153833
J Clin Oncol. 2023 Mar 20;41(9):1747-1757
pubmed: 36512738
Oncologist. 2021 Oct;26(10):854-864
pubmed: 34251745
Lancet Oncol. 2015 Oct;16(13):1344-54
pubmed: 26361969
World J Gastroenterol. 2016 Apr 21;22(15):4034-40
pubmed: 27099447
Nature. 2019 Mar;567(7747):257-261
pubmed: 30814741
Hepatology. 2016 May;63(5):1517-27
pubmed: 26426978
J Gastroenterol. 2021 Jan;56(1):90-100
pubmed: 33278003
Nat Cancer. 2021 Sep;2(9):891-903
pubmed: 34796337
Expert Opin Pharmacother. 2018 Aug;19(11):1167-1170
pubmed: 30011239
Drugs. 2023 Jan;83(1):93-102
pubmed: 36571670
J Hepatol. 2019 Aug;71(2):265-273
pubmed: 30959157
BMJ Open. 2022 Sep 17;12(9):e060955
pubmed: 36115673
Liver Int. 2017 Aug;37(8):1193-1201
pubmed: 28111883
HPB (Oxford). 2020 May;22(5):677-689
pubmed: 31607637
J Clin Oncol. 2020 Jan 20;38(3):193-202
pubmed: 31790344
Dig Dis Sci. 2019 Oct;64(10):3013-3019
pubmed: 30937719
PLoS One. 2017 Mar 24;12(3):e0174222
pubmed: 28339493
BMC Cancer. 2021 Mar 23;21(1):301
pubmed: 33757459
Clin J Gastroenterol. 2021 Jun;14(3):699-713
pubmed: 33774785
Hepatology. 2016 Jul;64(1):106-16
pubmed: 26765068
J Hepatocell Carcinoma. 2022 Aug 31;9:929-946
pubmed: 36068876
Gut. 2018 Feb;67(2):362-371
pubmed: 27789659
Lancet. 2018 Mar 24;391(10126):1163-1173
pubmed: 29433850
Lancet Oncol. 2022 Aug;23(8):995-1008
pubmed: 35798016
Oncoimmunology. 2018 Nov 22;8(2):e1546068
pubmed: 30713806
Front Oncol. 2022 Sep 21;12:985380
pubmed: 36212494
Cochrane Database Syst Rev. 2009 Jan 21;(1):CD001199
pubmed: 19160192
Nature. 2014 Nov 27;515(7528):563-7
pubmed: 25428504
Hepatology. 2021 Nov;74(5):2544-2560
pubmed: 34036623
Lancet Oncol. 2020 Jul;21(7):947-956
pubmed: 32615109
World J Gastroenterol. 2019 May 28;25(20):2524-2538
pubmed: 31171895
Arch Med Sci. 2017 Oct;13(6):1383-1393
pubmed: 29181069
J Immunol. 2017 Nov 1;199(9):3348-3359
pubmed: 28939757
Clin Cancer Res. 2021 Sep 1;27(17):4848-4858
pubmed: 34108184
Gut. 2014 May;63(5):844-55
pubmed: 24531850
Ann Surg Oncol. 2014 Jul;21(7):2429-35
pubmed: 24619495
Gastroenterology. 2019 May;156(6):1683-1692.e1
pubmed: 30660729
Am J Transl Res. 2019 Mar 15;11(3):1428-1445
pubmed: 30972172
J Hepatol. 2022 Mar;76(3):681-693
pubmed: 34801630
Hepatology. 2013 Jul;58(1):139-49
pubmed: 22961630
N Engl J Med. 2020 May 14;382(20):1894-1905
pubmed: 32402160
Oncol Lett. 2017 Feb;13(2):984-992
pubmed: 28356989
Lancet. 2000 Sep 2;356(9232):802-7
pubmed: 11022927
Hum Vaccin Immunother. 2014;10(4):970-6
pubmed: 24419174
Cancers (Basel). 2022 May 04;14(9):
pubmed: 35565424
World J Gastroenterol. 2016 Jun 21;22(23):5384-92
pubmed: 27340354
J Hepatocell Carcinoma. 2021 Oct 05;8:1233-1240
pubmed: 34676181
J Gastrointest Cancer. 2020 Dec;51(4):1193-1196
pubmed: 32869146
JAMA Surg. 2018 Oct 1;153(10):e182721
pubmed: 30073257
Oncoimmunology. 2015 Oct 12;5(3):e1083671
pubmed: 27141337
Liver Int. 2020 Feb;40 Suppl 1:109-115
pubmed: 32077602
J Hepatol. 2018 Jul;69(1):182-236
pubmed: 29628281
Hepatology. 2022 Oct;76(4):1000-1012
pubmed: 35313048
Oncoimmunology. 2017 May 16;6(7):e1328335
pubmed: 28811965
Semin Cancer Biol. 2018 Oct;52(Pt 2):117-124
pubmed: 29229461
J BUON. 2016 Sept-Oct;21(5):1189-1194
pubmed: 27837622
Liver Transpl. 2015 Sep;21(9):1142-52
pubmed: 25981135
JGH Open. 2020 Mar 20;4(4):713-721
pubmed: 32782961
Cancers (Basel). 2021 May 30;13(11):
pubmed: 34070800
Ann Surg. 2018 Dec;268(6):943-954
pubmed: 29521740
Nature. 2017 May 4;545(7652):60-65
pubmed: 28397821
Viruses. 2022 Mar 22;14(4):
pubmed: 35458386
Dig Liver Dis. 2016 Nov;48(11):1275-1282
pubmed: 27481586
Ir J Med Sci. 2023 Jun;192(3):1065-1071
pubmed: 35996068
Lancet Gastroenterol Hepatol. 2022 Mar;7(3):219-229
pubmed: 35065058
Biosci Trends. 2014 Dec;8(6):333-8
pubmed: 25641180
J Hepatol. 2012 Feb;56(2):412-8
pubmed: 21756858
Hepatol Res. 2014 May;44(5):523-31
pubmed: 23672310
Adv Cancer Res. 2021;149:1-61
pubmed: 33579421
Am J Cancer Res. 2021 Jul 15;11(7):3711-3725
pubmed: 34354870
Eur Rev Med Pharmacol Sci. 2020 Jan;24(2):983-987
pubmed: 32017007
World J Gastroenterol. 2023 Feb 28;29(8):1243-1260
pubmed: 36925456
J Hepatol. 2016 Oct;65(4):719-726
pubmed: 27084592
Future Oncol. 2021 Apr;17(10):1237-1251
pubmed: 33307782
Gut. 2022 Mar;71(3):593-604
pubmed: 33741640
Lancet. 2022 Oct 15;400(10360):1345-1362
pubmed: 36084663
Dig Liver Dis. 2009 Jan;41(1):36-41
pubmed: 18818130
J Hepatol. 2018 Dec;69(6):1284-1293
pubmed: 30236834
J Clin Med. 2021 Jan 11;10(2):
pubmed: 33440759
J Gastroenterol Hepatol. 2015 Nov;30(11):1643-50
pubmed: 25974743
Front Oncol. 2022 Nov 24;12:1051916
pubmed: 36505833
J Exp Med. 2015 Feb 9;212(2):139-48
pubmed: 25601652
Am J Surg. 2022 Jul;224(1 Pt B):494-500
pubmed: 35115174
Onco Targets Ther. 2019 Jul 17;12:5779-5791
pubmed: 31410023
Onco Targets Ther. 2019 Jan 11;12:541-548
pubmed: 30666133
Lancet Gastroenterol Hepatol. 2022 Mar;7(3):208-218
pubmed: 35065057
J Clin Transl Hepatol. 2021 Oct 28;9(5):738-748
pubmed: 34722189